Refine
Has Fulltext
- yes (871)
Is part of the Bibliography
- yes (871) (remove)
Year of publication
- 2021 (871) (remove)
Document Type
- Journal article (871) (remove)
Language
- English (871) (remove)
Keywords
- COVID-19 (19)
- inflammation (16)
- virtual reality (13)
- inorganic chemistry (11)
- SARS-CoV-2 (10)
- boron (10)
- immunohistochemistry (8)
- breast cancer (7)
- ischemic stroke (7)
- machine learning (7)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (130)
- Institut für Anorganische Chemie (50)
- Medizinische Klinik und Poliklinik I (49)
- Institut für Psychologie (47)
- Medizinische Klinik und Poliklinik II (44)
- Institut für Geographie und Geologie (40)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (37)
- Pathologisches Institut (36)
- Institut für Organische Chemie (33)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (31)
Sonstige beteiligte Institutionen
- Ökologische Station Fabrikschleichach (2)
- Apotheke, Universitätsklinikum Würzburg (1)
- Bundeswehr Institute of Radiobiology affiliated to the University of Ulm, Munich, Germany (1)
- Clinical Trial Center (CTC) / Zentrale für Klinische Studien Würzburg (ZKSW) (1)
- Department of Cellular Biochemistry, University Medical Center Göttingen (1)
- Department of Nuclear Medicine, Philipps University Marburg, Marburg, Germany (1)
- Georg August University School of Science (1)
- Helmholtz Institute for RNA-based Infection Biology (HIRI), Josef-Schneider-Straße 2/D15, DE-97080 Wuerzburg, Germany (1)
- IZKF Nachwuchsgruppe Geweberegeneration für muskuloskelettale Erkrankungen (1)
- Institute of Cancer Research (ICR) London (1)
Remdesivir is the only FDA-approved drug for the treatment of COVID-19 patients. The active form of remdesivir acts as a nucleoside analog and inhibits the RNA-dependent RNA polymerase (RdRp) of coronaviruses including SARS-CoV-2. Remdesivir is incorporated by the RdRp into the growing RNA product and allows for addition of three more nucleotides before RNA synthesis stalls. Here we use synthetic RNA chemistry, biochemistry and cryoelectron microscopy to establish the molecular mechanism of remdesivir-induced RdRp stalling. We show that addition of the fourth nucleotide following remdesivir incorporation into the RNA product is impaired by a barrier to further RNA translocation. This translocation barrier causes retention of the RNA 3ʹ-nucleotide in the substrate-binding site of the RdRp and interferes with entry of the next nucleoside triphosphate, thereby stalling RdRp. In the structure of the remdesivir-stalled state, the 3ʹ-nucleotide of the RNA product is matched and located with the template base in the active center, and this may impair proofreading by the viral 3ʹ-exonuclease. These mechanistic insights should facilitate the quest for improved antivirals that target coronavirus replication.